8-K: Tango Therapeutics Reports Strong Vopimetostat Phase 1/2 Data

Tango Therapeutics disclosed preliminary cash of $152.8M and positive Phase 1/2 clinical trial results for vopimetostat, showing durable tumor control and favorable tolerability across multiple cancer types.

Summary

• Preliminary unaudited cash, cash equivalents, and marketable securities were $152.8 million as of September 30, 2025.
• Vopimetostat (TNG462), an oral, once-a-day, MTAP-selective PRMT5 inhibitor, demonstrated robust and durable clinical activity in multiple MTAP-deleted cancer types.
• The overall response rate (ORR) was 27% across cancer types, with a median progression-free survival (mPFS) of 6.4 months and a disease control rate (DCR) of 78%.
• In second-line (2L) MTAP-deleted pancreatic cancer, vopimetostat achieved an ORR of 25% and an mPFS of 7.2 months.
• The histology agnostic cohort (excluding sarcoma, pancreatic, and lung cancer) showed an ORR of 49% and an mPFS of 9.1 months.
• Vopimetostat exhibited a potential best-in-class safety and tolerability profile, with no drug-related dose discontinuations and approximately 8% dose reduction, suggesting good combinability.
• The FDA has agreed on a 250 mg QD go-forward dose for vopimetostat.
• A pivotal study in 2L pancreatic cancer is planned to initiate in 2026, aiming for rapid enrollment of approximately 300 patients.
• Ongoing combination studies of vopimetostat with RAS(ON) inhibitors (daraxonrasib or zoldonrasib) are showing early signs of activity and tolerability, with expansion to a first-line (1L) cohort planned.
• The lung cancer cohort is fully enrolled (n=41), with emerging data consistent with expectations, and an update planned for 2026.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for vopimetostat across multiple cancer types, particularly in pancreatic cancer, with superior efficacy and safety compared to historical controls and competitors. The planned pivotal study and combination strategies indicate a clear path forward. The preliminary cash position is also noted. The primary negative is the unaudited nature of the financial data and the inherent risks of drug development, including the need for future capital raises.

Positives

• Preliminary cash, cash equivalents, and marketable securities of $152.8 million as of September 30, 2025.
• Vopimetostat demonstrated robust and durable clinical activity with an overall response rate (ORR) of 27% across cancer types.
• Median progression-free survival (mPFS) of 7.2 months and ORR of 25% in second-line (2L) MTAP-deleted pancreatic cancer, supporting a planned pivotal study.
• Achieved 49% ORR and 9.1 months mPFS in the histology agnostic cohort (excluding sarcoma), indicating strong activity in multiple late-line cancer types.
• Potential best-in-class safety and tolerability profile with no drug-related dose discontinuations and only ~8% dose reduction, suggesting good combinability.
• FDA agreement on the 250 mg QD go-forward dose.
• Robust enrollment in ongoing combination studies with RAS(ON) inhibitors, showing early signs of activity and tolerability.
• Pivotal study in 2L pancreatic cancer planned for 2026, with potential to be first-to-market.
• Lung cancer cohort fully enrolled with emerging data consistent with expectations.

Negatives

• Preliminary financial information is unaudited and subject to change during the company's financial closing procedures.
• The company has a limited operating history and has not generated any revenue to date from drug sales.
• The company anticipates continued operating losses for the foreseeable future.
• Sarcoma patients showed 0% ORR (n=9) in the vopimetostat trial.

Risks

• Limited operating history and no revenue from drug sales to date, with no guarantee of future profitability.
• Future clinical trial data releases may differ materially from initial or interim data.
• Limited experience with conducting clinical trials and reliance on third parties, potentially leading to delays in trial commencement, patient enrollment, dosing, or result generation.
• Dosing in clinical trials may be delayed or stopped due to site issues, safety concerns, or supply disruptions.
• Significant changes to IND applications or protocols could substantially delay ongoing clinical trials.
• Benefits observed in preclinical experiments may not translate to clinical trials or commercial use, or may not be safe and/or effective in humans.
• Need to raise capital in the future; inability to do so on attractive terms could force delays, reductions, or discontinuation of development programs or commercialization efforts.
• Potential inability to advance preclinical development programs into and through the clinic for safety or efficacy reasons, or significant delays due to factors beyond control.
• Product candidates may cause adverse or undesirable side effects, potentially delaying or preventing regulatory approval.
• Dependence on third parties for conducting clinical trials and producing drug product.
• Ability to obtain and maintain patent and other intellectual property protection for technology and product candidates may not be sufficiently broad.
• Delays and other impacts on product development and clinical trials from public health events.
• The company's approach to drug discovery and development is novel and unproven, making it difficult to predict time, cost, and likelihood of success.
• May expend resources on less profitable or less likely to succeed product candidates or indications.

Future Outlook

Tango Therapeutics plans to initiate a pivotal study for vopimetostat in second-line MTAP-deleted pancreatic cancer in 2026, aiming for rapid enrollment and potential first-to-market approval. The company also anticipates providing updates on its lung cancer cohort and combination studies with RAS(ON) inhibitors in 2026, with the potential to support a first-line pivotal study for pancreatic and lung cancer. Management believes vopimetostat has the potential to be a best-in-class molecule for multiple MTAP-deleted solid tumors and a turning point in hard-to-treat cancers.

Management Comments

• The Company estimates that it had $152.8 million of cash, cash equivalents and marketable securities as of September 30, 2025.

Industry Context

The oncology industry is actively pursuing targeted therapies for difficult-to-treat cancers, particularly those with specific genetic alterations like MTAP deletion. PRMT5 inhibitors represent a promising class of drugs in this space. Tango Therapeutics' vopimetostat, with its demonstrated durable tumor control and favorable tolerability, positions the company as a significant player in addressing high unmet medical needs in pancreatic, lung, and other MTAP-deleted solid tumors. The ongoing combination studies with RAS(ON) inhibitors align with the industry trend of exploring synergistic drug combinations to improve efficacy and overcome resistance mechanisms in cancer treatment.

Comparison to Industry Standards

• Vopimetostat's overall response rate (ORR) of 27% across cancer types is presented as 'currently best-in-class' compared to previously reported data for BMS504 (ORR 23% at ASCO 2025) and AMG193 (ORR 21% at ESMO 2024).
• In second-line (2L) pancreatic cancer, vopimetostat's median progression-free survival (mPFS) of 7.2 months is more than twice the historical standard of care (SOC) chemotherapy trials, which typically report 2L mPFS of 2-3.5 months and ORR of approximately 10%.
• The 9.1 months mPFS in the histology agnostic cohort also significantly exceeds historical SOC trials in multiple late-line, difficult-to-treat cancers.
• The safety profile, with no drug-related dose discontinuations and ~8% dose reduction, suggests superior tolerability compared to many existing cancer therapies, enhancing its potential for combination regimens.

Stakeholder Impact

• Shareholders: Positive clinical data and clear development path could increase investor confidence and share value. The need for future capital raises could lead to dilution.
• Patients: Vopimetostat offers a potential new treatment option with durable tumor control and favorable tolerability for hard-to-treat MTAP-deleted cancers, including pancreatic and lung cancer, where current standard of care is limited.
• Employees: Continued progress in clinical development and potential market entry could provide job security and growth opportunities.
• Competitors: The 'best-in-class' claims and strong data for vopimetostat could intensify competition in the PRMT5 inhibitor and MTAP-deleted cancer treatment markets.

Next Steps

• Finalize pivotal study design for 2L pancreatic cancer through interaction with the FDA later this quarter.
• Initiate pivotal study in 2L pancreatic cancer in 2026.
• Provide an update on lung cancer cohort safety and efficacy data and development plans in 2026.
• Provide an update on initial 2L+ safety and efficacy data for vopimetostat + daraxonrasib or zoldonrasib combination in 2026.
• Provide an update on initial 1L pancreatic combination data and durability update on 2L+ cohort in 2026.
• Continue enrollment in combination studies with RAS(ON) inhibitors, with planned expansion to a first-line cohort.

Key Dates

Recommendation

The clinical update for vopimetostat presents compelling efficacy and safety data, positioning it as a potential best-in-class PRMT5 inhibitor. The demonstrated superior ORR and mPFS compared to both historical standard of care and direct competitors in challenging cancer types like pancreatic cancer, coupled with a favorable tolerability profile, significantly de-risks the development program. The clear path to a pivotal study in 2L pancreatic cancer by 2026 and the promising combination strategies with RAS(ON) inhibitors for 1L indications suggest substantial market potential. While the company will need to raise capital, the strong clinical results are likely to attract favorable financing terms. This filing indicates a significant positive inflection point for the company's lead asset.

Keywords

Tango Therapeutics, Vopimetostat, TNG462, PRMT5 inhibitor, MTAP-deleted cancer, Pancreatic cancer, Lung cancer, Oncology, Clinical trial, Phase 1/2, RAS(ON) inhibitors, Drug development, Biotechnology, SEC filing, 8-K, Financial results, Cash position, Clinical update